The effect of metformin on treatment of squamous cell carcinoma of neck

To evaluate the efficacy and safety of adding metformin to chemoradiation of patients with squamous cell carcinoma of hypopharynx, nasopharynx, and larynx

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191203045594N1

Enrollment

Registered

2019-12-12

Start date

2019-12-18

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasm of larynx. Malignant neoplasm of larynx, unspecified

Interventions

Intervention group: The patients with proven diagnosis of squamous cell carcinoma of hypopharynx, nasopharynx, and larynx receiving concurrent chemoradiation will take metformin orally twice daily (10

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients with biopsy-proven squamous cell carcinoma of hypopharynx, nasopharynx, and larynx

Exclusion criteria

Exclusion criteria: All patients with distant metastasis Hypersensitivity to metformin

Design outcomes

Primary

Measure	Time frame
The complete response. Timepoint: 12 weeks after the intervention. Method of measurement: Spiral CT scan.;Toxicity. Timepoint: Weekly. Method of measurement: Common Terminology Criteria for Adverse Events (CTCAE).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Adelpour

Shiraz University of Medical Sciences

adelpourz@sums.ac.ir+98 71 3647 4320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026